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PRL-3 is essentially overexpressed in primary colorectal tumours
and associates with tumour aggressiveness
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Phosphatase PRL-3 has been involved in different types of cancer, especially in metastases from colorectal carcinoma (CRC). In this
study, we explored both isoforms of PRL-3 as a biomarker to predict the recurrence of stage IIIB-C CRC. Overexpression of PRL-3
was investigated in primary human colorectal tumours (n¼ 20) and hepatic metastases (n¼ 36) xenografted in nude mice, samples
characterised by absence of human non-tumoral cells, showing a high degree of expression in metastases (P¼ 0.001). In 27 cases of
matched normal colonic mucosa/primary tumour/hepatic metastases, PRL-3 overexpression occurs in primary tumours vs normal
mucosa (P¼ 0.001) and in hepatic metastases vs primary tumours (P¼ 0.045). Besides, our results in a series of 80 stage IIIB-C CRC
primary tumours showed that high levels of PRL-3 were an independent predictor of metastasis (Po0.0001; OR: 9.791) in
multivariate analysis of a binary logistic regression and that PRL-3 expression tightly correlates with parameters of bad outcome.
Moreover, PRL-3 expression associated with poor outcome in univariate (Po0.0001) and multivariate Cox models (hazard ratio:
3.322, 95%, confidence interval: 1.405–7.852, P¼ 0.006). In conclusion, PRL-3 is a good marker of aggressiveness of locally advanced
CRS and a promising predictor of distant metastases. Nevertheless, for prognosis purposes, it is imperative to validate the cutoff value
of PRL-3 expression in a larger and consecutive series and adjuvant setting.
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Colorectal carcinoma (CRC) is the third most prevalent cancer in
the world. When CRC is detected early, the 5-year survival rate is
approximately 90%, but only 35–40% of CRC are diagnosed at this
stage. In the bulk of the patients, CRC is detected when lymph
node metastases are present and a significant number of cases are
diagnosed with disease in distant sites, especially in the liver.
Despite the clinical importance of metastasis being responsible for
most cancer deaths, much remains to be learned about the biology
of the metastatic process.
Protein tyrosine phosphatases (PTPs) are key regulatory
enzymes in various signal transduction pathways. The PRL
phosphatases represent a novel subfamily of PTPs comprising
three members (PRL-1, PRL-2 and PRL-3) sharing a high degree
(475%) of amino-acid sequence identity. PRL-1 was originally
identified as an immediate early gene in regenerating liver (Mohn
et al, 1991). Overexpression of PRL-1 and PRL-2 transformed
mouse fibroblasts and hamster pancreatic epithelial cells in culture
(Cates et al, 1996), and promoted tumour growth in nude mice
(Diamond et al, 1994). PRL-3 gene, located in 8q24-3, has been
involved in processes of migration, invasion and metastasis in
different types of cancer (Miskad et al, 2004, 2007; Wu et al, 2004;
Polato et al, 2005; Radke et al, 2006; Wang et al, 2006; Qian et al,
2007). Initially, specific overexpression of PRL-3 in colorectal
cancer liver metastases (LMs) was observed when compared with
matched primary tumours in association with gene amplification
(Saha et al, 2001; Bardelli et al, 2003). Kato et al, using in situ
hybridisation, reported that primary tumours showed variable
degrees of PRL-3 expression that associated with lung or liver
dissemination (Kato et al, 2004). These findings were also
reproduced when protein expressed was assessed using non-
commercial antibodies. In this study, we aimed to analyse the
relative contribution of cancer cells and stroma to the expression
of PRL-3 in primary CRC and metastases and to determine
whether quantitative RT-PCR (qRT-PCR) could be a good
alternative to quantitatively analyse PRL-3 expression in routinely
collected specimens and explore their putative clinical usefulness.
MATERIALS AND METHODS
Tumour samples
All patients gave written consent to give tumour samples to the
Hospital Universitari de Bellvitge tumour bank, and the ethics
committee of the hospital cleared the tumour harvesting and
grafting protocols.
Xenografts Twenty primary human colorectal tumours and 36
LMs from CRCs were grafted into 5-to-6-week-old male nu/nu
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Swiss mice weighing 18– 22 g (Harlan, Barcelona, Spain). Mice
were anaesthetised using isofluorane inhalation. A 2-mm3 piece of
primary colorectal tumour and LM were anchored to the caecum
or the anterior hepatic lobe, respectively. All experiments were
approved by the Institutional Animal Care Committee. After a
growth period ranging from 2 to6 months, xenografts were excised
and immediately frozen in dry ice. These samples are characterised
by the absence of non-tumoral human cells because of the mice
desmoplastic reaction.
Matched microdissected samples Six sets of matched primary
tumour stromal cells, primary tumour cancer cells, LM stromal
cells and LM cancer cells corresponding to six different patients
were microdissected using the Arcturus-PixCell-II Laser Capture
Microdissection System. RNA extraction was performed using
the TrizOl reagent and glycogen to increase the yield of the
procedure.
Matched triplet samples Twenty-seven matched triplets of fresh-
frozen non-adjacent normal colonic mucosa, primary tumour and
LM (22 synchronous and five metachronous) were obtained
between January 2001 and December 2005 from the Department
of Pathology, Hospital Universitari de Bellvitge, Barcelona, Spain.
Metastatic CRC (mCRC) and paired non-adjacent normal mucosa
fresh-frozen specimens Eighty primary metastatic colorectal
tumours (46 stage IIIB and 34 stage IIIC) and their correspondent
normal colonic mucosa were obtained from the Pathology
Department of the Hospital Universitari de Bellvitge. Among the
80 CRCs, we classify 43 CRCs (29 stage IIIB and 14 stage IIIC) that
did not develop distant metastases for at least 60 months and 37
CRCs (17 stage IIIB and 20 stage IIIC) that developed liver and/or
lung metastases.
All patients underwent surgical resection: 70 radical and 10
palliative surgeries. All patients received chemotherapy adjuvant
treatment. Median follow-up was 107.30 months (range 43–132).
End points were local recurrence for disease-free survival (DFS)
and cancer-related death or last follow-up for OS. At the end of the
follow-up period, 45 of 80 patients (56.25%) were alive without
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Figure 1 (A) Normalised expression of PRL-3 in xenografts determined by quantitative –PCR. Boxplots comparing PRL-3 mRNA expression in 20
human colorectal primary tumours and 36 liver metastases from CRC raised as xenografts in nu/nu Swiss mice. (B) Normalised expression of PRL-3
determined by Quantitative –PCR in paired samples of microdissected specimens. We analysed four different cell populations from six different patients: (i)
primary tumour stromal cells, (ii) primary tumour cancer cells, (iii) hepatic metastases stromal cells and (iv) hepatic metastases cancer cells, obtained by
means of Arcturus PixCell II Laser-Capture microdissection system. (C) Boxplots comparing PRL-3 mRNA normalised expression in 27 matched fresh-
frozen samples of non-adjacent normal mucosa, primary tumour and liver metastases (22 synchronous and five metachronous). Comparing normal colonic
mucosa and primary tumours, pair-wise fixed reallocation randomisation test (Pfaffl, 2001) showed significantly higher expression in carcinomas by the factor
23.133 (Po0.001). Besides, liver metastases displayed a higher expression than primary colorectal tumours (factor 1.983; P¼ 0.045). (D) Bars displayed the
overexpression of isoform 1 PRL-3 in 23 out of 27 liver metastases. Bars represent the ratio among PRL-3 normalised expression in liver metastases divided
by PRL-3 normalised expression in its paired primary tumour. The ratio was expressed as fold changes. In all experiments, the level of PRL-3 expression was
expressed as absolute expression normalising for b2-microglobuline as housekeeping control gene. All experiments were performed in triplicate using two
different retrotranscriptions.
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disease, six (7.5%) were alive with disease and 29 died because of
cancer.
Quantitative real-time RT–PCR analysis
Total RNA was retrieved from all tissue specimens using the
TrizOL Reagent method. cDNA was obtained using recombinant
ribonuclease inhibitor RNAse OUT and M-MLV retrotranscriptase.
Quantitative real-time RT–PCR analyses were performed using the
Light-Cycler 2.0 Roche System and the LightCycler FastStart DNA
Master SyBR Green I kit (Roche). Oligonucleotide sets for RT–
PCR amplification of PRL-3 were as follows: PRL-3 isoform 1: up/
50-GGGACTTCTCAGGTCGTGTC-30; down/50-AGCCCCGTACTTC
TTCAGGT-30; PRL-3 isoform 2, up/50-GGGACTTCTCAGGTCG
TGTC-30; down/50-GCGCTTCCGGCCCAG-30. To amplify PRL-3
in xenograft samples, we use human-specific oligonucleotides to
avoid the amplification of murine PRL-3: up/50-GTGAAGGCCAAG
TTCTGT-30; down/50-ACAAGGACTGGAGCCCGG-30. For normal-
isation of PRL-3 expression levels, we analysed the expression of
human-specific b2-microglobulin, a housekeeping gene widely
used in qPCR with CRC samples (Haller et al, 2004; Rubie et al,
2005; Abal et al, 2007; Menendez et al, 2008): up/50-CCCACTGA
AAAAGATGAG-30; down/50-CCTCCATGATGCTGCTT-30. Human-
specific E-cadherin was used as a control between xenografts and
paired primary tumours to evaluate the influence of expression
rates in epithelial cells because of the different phylogenetic origin
of stromal cells (up/50-CCTATTTTTCCCTCGACA-30; down/50-G
CAATTCTGCTTGGATTC-30). We used cyclophillin to check the
stability of the b2-microglobulin expression in the entire group of
samples (up/50-TTCTTCGACATTGCCGT-30; down/50-TGCTGTCT
TTGGGACC-30). All of the experiments were performed in
triplicate using two different retrotranscriptions.
Immunohistochemical analysis
The 3 mm slices of paraffin-embedded tissue were used. For antigen
retrieval, the slides were boiled after deparaffinization in a
pressure cooker for 2 min in citrated buffer (8.2 mM trisodium
citrate and 1.98 mM citric acid, pH6), and endogen peroxidase was
blocked with 3% H2O2 for 20 min. After blocking for 30 min with 1/
5 dilution of goat serum, the primary antibodies were incubated
for 1 h at room temperature. Primary antibodies were polyclonal
antibodies for PRL-3 (rabbit anti-PRL-3, Zymed Laboratories,
Invitrogen, Carlsbad, MA, USA, and rabbit anti-PRL-3, ab50276
Abcam, Cambridge, UK), diluted 1 : 500 in phosphate-buffered
saline (PBS). Reaction was visualised using the EnVision antirabbit
antibody system and developed using the DAB-Plus Kit (Dako,
Copenhagen, Denmark). Slides were counterstained with Harry’s
modified haematoxylin. As a negative control, we used the
EnVision antirabbit antibody system that displayed no reactivity
against any antigen.
A PRL-3 related protein-blocking experiment was performed.
Before the staining protocol, PRL-3 polyclonal antibodies were
incubated for 1 h at room temperature with an excess of PRL-1 or
PRL-2 or PRL-3 blocking protein (Abcam, Cambridge, UK). The
antibody that is bound to the blocking protein is no longer
available to bind to the epitope present in the protein on the tissue.
Blinded analysis of the slides was performed by two independent
observers (NB and DGM).
Western blot analysis
1mg of human recombinant PRL-1, PRL-2 and PRL-3 (Abcam,
Cambridge, UK) was heated at 951C for 5 min, electrophoresed through
18% SDS–polyacrilamide gel and transferred onto a nitrocellulose
membrane. PRL-3 was immunodetected by using two different
antibodies: rabbit anti-PRL-3 (Zymed Laboratories, Invitrogen, Carls-
bad, MA, USA) and rabbit anti-PRL-3, ab50276 (Abcam, Cambridge,
UK), both diluted 1 : 500 and incubated overnight at 41C. Secondary
antibody antirabbit IgG coupled with horseradish peroxidase was
incubated for 30 min at room temperature. The ECL kit (Amersham
General Electric) was used for detection.
Statistical analysis
REST-XLr relative expression software tool was used to evaluate
PRL-3 expression in which expression ratios are tested for
significance by a pair-wise fixed reallocation randomisation test
(Pfaffl, 2001).
Moreover, independent samples t-test was applied in xenografts
and mCRC samples, and paired samples t-test, in matched triplet
samples and paired normal colonic mucosa/mCRC.
Association between PRL-3 expression and clinicopathological
variables was assessed by the w2-test. Survival was defined as the time
from the date of primary tumour resection until death, being censored
for patients who were alive at the time of the last follow-up. Survival
curves were estimated using the Kaplan–Meier method. Cox’s
proportional hazard models were fitted to estimate hazard ratios
(HRs), and 95% confidence interval (CI) and likelihood ratio tests were
performed to assess the statistical significance of the variables.
Binary logistic regression was performed to identify the
predictors for distant dissemination.
RESULTS
PRL-3 is specifically expressed in tumour colorectal cells
To investigate the specificity of PRL-3 expression in colorectal
cancer cells, a set of xenografts from primary colorectal tumours
Table 1 Statistical analysis of PRL-3 expression (change fold) in matched triplet samples and stage IIIB-C primary tumours with evidenced metachronous
metastasis (mCRC-met) and without evidenced metachronous metastasis (mCRC-nomet)
Expression ratio Pair-wise randomisation test Paired samples t-test Independent samples t-test
Matched samples
Primary tumour/normal mucosa 23.133 0.001 o0.001 —
Liver metastasis/primary tumour 1.983 0.045 o0.001 —
Stage IIIB-C primary tumours
mCRC-nomet/paired normal mucosa 7.743 0.001 o0.001 —
mCRC-met/paired normal mucosa 47.38 0.001 o0.001 —
mCRC-met/mCRC-nomet 4.190 0.001 — 0.004
REST-XLr relative expression software tool was used to evaluate PRL-3 expression in which expression ratios are tested for significance by a pair-wise fixed reallocation
randomisation test (Pfaffl, 2001), and plotted using standard error estimation through a complex Taylor algorithm. REST-XLr performs 10 000 random reallocations of samples
and controls between the groups, and counts the number of times the relative expression of the randomly assigned group is greater than the sample data. Moreover,
independent samples T-test was applied in mCRC samples, and paired samples t-test, in matched triplet samples and paired normal colonic mucosa/mCRC.
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(n¼ 20) and LM from CRC (n¼ 36) were analysed. Xenografts are
characterised by the lack of human stroma providing a good model
to study the specificity of the tumour cell population expression.
Using human-specific oligonucleotides, PRL-3 expression was
already detected in orthotopic xenografts derived from primary
CRC, although at low levels (Figure 1A). Metastasis xenografts
implanted in the mouse liver showed higher levels (7.2-fold;
U-Mann–Whitney Po0.001)) when compared with primary CRC
ones. Using oligonucleotides that selectively amplify the murine
PRL-3, very low or absent PRL-3 expression was detected both in
primary and LM xenografts (data not shown) disregarding a
relevant contribution from the mouse stroma to the total amount
of PRL-3 in the xenografts, even endothelial cells. To give further
insight into the value of using xenografts for RNA expression
purposes, we compared, as a control, the expression of E-cadherin
between 20 xenografts derived from primary colorectal tumours
and its paired human primary tumours. No differences were
observed among the two groups (P¼ 0.69; Supplementary Figure
S1), ruling out a possible artefact of transplantation among species
on the expression of cancer-involved proteins.
To further confirm that PRL-3 expression is specific of tumour
cells, microdissection was performed in a set of six matched
primary tumour/LM samples. Again, expression was observed in
all primary tumour cancer cells and at a lower degree in the
corresponding stroma. In five out of six cases, overexpression was
evident in the metastasic lesion when compared with primary
tumours (Figure 1B). Although some degree of expression was
detected in the stroma, probably related to endothelial cells as
reported earlier (Bardelli et al, 2003), expression levels were
mainly residual.
Both PRL-3 isoforms are overexpressed in the primaries.
The overexpression is further selected during distal
dissemination
To analyse whether PRL-3 overexpression was mainly a metastasis-
specific event or was already present at significant levels in
primaries, we analysed a set of 27 matched triplets of normal
colonic mucosa/primary tumour/LM (22 synchronous, five meta-
chronous). As depicted in Table 1 and figure 1C, PRL-3 isoform 1
was consistently overexpressed (23.1-fold) in primary tumours in
relation to its paired normal mucosa (P¼ 0.001). Isoform 2 was
also upregulated in primary tumours, although at a lower intensity
(three-fold when compared with paired normal mucosa;
P¼ 0.001), contributing to higher PRL-3 levels in primary tumours
in relation to its counterpart normal mucosa.
Further upregulation of both PRL-3 isoforms was evidenced in
matched LM (isoform 1, two-fold; P¼ 0.045; isoform 2, 1.5-fold;
P¼ 0.003; Table 1). This overexpression was evident in 23 out of 27
LMs for isoform 1 (Figure 1D) and in 21 out of 27 LMs for isoform 2.
PRL-3 expression levels in primary colorectal tumours
associates with tumour aggressiveness
We analysed a selected set of 80 stage III colorectal carcinomas
with a similar proportion of recurrent (N¼ 37) and non-recurrent
(N¼ 43) cases. To dichotomise a continuous variable, PRL-3
normalised expression for each of the 80 stage III primary tumours
adjusted for their counterpart normal mucoses was calculated
(Figure 2A). On account of the data that did not fit a normal
distribution, outlier values were coded as ‘high expression’.
Therefore, the cutoff was calculated with the values (N¼ 72) that
fit a normal distribution (Figure 2B). Accordingly, PRL-3
expression was coded as a categorical variable. Binary logistic
regression showed that PRL-3 expression was a predictor of
distant metachronous metastasis in univariate analysis (P¼ 0.000;
Table 2). In multivariate analysis, the high level of PRL-3 was the
only independent predictor of metastasis (Po0.0001; OR: 9.791;
Table 2). Consequently, 28 out of 38 primary tumours (73.7%)
displaying high PRL-3 expression eventually developed liver or
lung metastases, whereas 33 out of 42 patients (78.6%) showing
low PRL-3 expression did not (w2-test, P¼ 0.000). When tumours
were classified according to the presence or absence of metastases,
the former showed a 4.190-fold average increase of PRL-3
expression (P¼ 0.001; Figure 3). Finally, 24 out of 38 patients
(63.15%) with high levels of PRL-3 expression displayed vascular
or lymphatic invasion, with the difference being statistically
significant in relation to low-expression cases (17 out of 42;
P¼ 0.035). These results point to a role of PRL-3 in the spreading
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Figure 2 (A) PRL-3 normalised expression for 80 primary tumours
adjusted for their counterpart normal mucoses. As values did not fit a
normal distribution (Kolmogorov–Smirnov test Po0.0001), extremely high
values plotted to the right of the dashed line were coded as ‘high
expression’. Values on the left of the dashed line (72 patients) were
evaluated to fit a normal distribution (Kolmogorov–Smirnov test
P¼ 0.113); therefore, in (B), we plotted values of PRL-3 expression for
the normally distributed values. Dashed line designates the median value
(cutoff) and separates two populations coded as ‘low expression’ and ‘high
expression’. Then, 38 values were coded as high expression and 42 values
as low expression.
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of CRC metastasis when primary cancer cells intravasate into
capillaries in agreement with Kato et al (2004).
We also performed an immunohistochemical staining of PRL-3
in this set of stage III colorectal carcinomas. As shown in Figure 4,
the PRL-3 antibody displayed an intense paranuclear and granular
staining probably related to the Golgi apparatus or transport
vesicles, both in the tumoral cells (Figure 4A) and normal colonic
mucosa (Figure 4B). Unexpected staining of normal mucosa led us
to check the specificity of this antibody performing IHC with a
previous blocking assay with an excess of PRL-1 or PRL-2 or PRL-
3. The staining persisted after blocking, and therefore the
antibodies have no reactivity against PRL-1, PRL-2 and PRL-3 in
their natural conformation, thus making the evaluation of PRL-3
overexpression with this immunohistochemical approach extre-
mely difficult. On the other hand, Western blot showed no
reactivity with PRL-1 and PRL-2 and strong staining for PRL-3
(Figure 4C).
High levels of PRL-3 expression in colorectal primary
tumours was associated with worse survival
As shown in Table 2 and Figure 5A, the expression of high levels
of PRL-3 was associated in univariate analysis with poorer
outcome (mean survival: 57.17±6.16 months for high expression
vs 87.12±5.75 months for low expression; HR 3.639; CI:
1.607–8.24; P¼ 0.002). Moreover, the expression of PRL-3 was
also associated with a shorter DFS (mean DFS: 41.98±6.207
months for high expression vs 76.01±5.759 months for low
expression; HR 5.926; CI: 2.54–13.805; Po0.0001; Figure 5B).
Besides, high PRL-3 expression was associated with poor overall
survival. Among patients with low PRL-3 expression, 80.95% (four
with disease) are alive, compared with only 44.738% (two with
disease) in the high PRL-3 expression group. In multivariate
analysis, the high level of PRL-3 was the only independent
predictor of survival in our selected set of cases (P¼ 0.006; HR:
3.322; CI: 1.405–7.852; Table 2) along with a stage for DFS
(Po0.0001 for PRL-3 expression; P¼ 0.020 for stage).
DISCUSSION
In this study, we show that phosphatase PRL-3 is an independent
marker of aggressiveness and distant dissemination of locally
advanced CRC and a useful tool to classify the accuracy of stage III
CRC regarding the risk of distant relapse.
The first studies on PRL-3 expression in CRC reported that this
phosphatase was restrictedly expressed in metastatic cancer cells
but not in earlier stages of tumorigenesis (Bardelli et al, 2003), and
stated that PRL-3 was undetectable in normal mucosa and non-
metastatic CRC. Later, authors hypothesised that PRL-3 expression
was required for the earlier phases of the metastatic process, such
as those required for invasion into the lymphatics or vasculature
Table 2 Descriptive statistic, univariate and multivariate analyses for PRL-3 and clinicopathological variables
Descriptive
Univariate Cox’s proportional
hazard model
Univariate binary
logistic regression
Multivariate Cox’s proportional
hazard model
Multivariate binary
logistic regression
N % Mean survival HR CI P-value OR CI P-value HR CI P-value OR CI P-value
Gender
Female 40 50 78.76±6.8 1 0.672–2.948 0.366 1 0.683–4.022 0.263 1 0.54–2.46 0.714 1 0.483–4.072 0.533
Male 40 50 67.04±5.8 1.407 1.658 1.153 1.403
Tumour stage
IIIB 4657.5 80.11±5.53 1 0.951–4.121 0.068 1 0.983–6.044 0.055 1 0.848–4.076 0.122 1 0.793–7.9 0.118
IIIC 3442.5 63.14±7.26 1.98 2.437 1.859 2.503
Location
Colon 5467.5 76.09±7.38 1 0.544–2.625 0.657 1 0.393–2.51 0.99 1 0.564–2.794 0.578 1 0.327–3.118 0.987
Rectum2632.5 71.36±5.68 1.195 1.006 1.255 1.009
Vascular or lymphatic invasion
No 3948.8 82.63±6.01 1 0.866–3.886 0.113 1 0.928–5.607 0.072 1 0.484–2.544 0.805 1 0.392–3.792 0.732
Yes 4151.3 63.64±6.41 1.834 2.282 1.110 1.219
PRL-3 expression
Low 4252.5 87.12±5.75 1 1.607–8.24 0.002 1 3.65–28.81o0.0001 1 1.405–7.852 0.006 1 3.308–28.98o0.0001
High 3847.5 57.17±6.16 3.639 10.267 3.322 9.791
Cox’s proportional hazard models were fitted to estimate hazard ratios (HRs), and 95% confidence interval (CI) and likelihood ratio tests were performed to assess the statistical
significance of the variables. Binary logistic regression was performed to identify predictors for distant dissemination.
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Figure 3 Normalised expression of PRL-3 in 43 metastatic colorectal
carcinomas (29 stage IIIB and 14 stage IIIC) that did not develop distant
metastasis for at least 60 months and 37 metastatic colorectal carcinomas
(17 stage IIIB and 20 stage IIIC) that developed distant metastases
determined by Quantitative PCR. Pair-wise fixed reallocation randomisa-
tion test showed a higher expression of PRL-3 in patients who developed
liver or lung metastasis (P¼ 0.001). The level of PRL-3 expression was
expressed as absolute expression normalising for b2-microglobuline as
housekeeping control gene.
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(Kato et al, 2004). In addition, an immunohistochemical approach
asserted that PRL-3 was a potential marker for LM of colorectal
cancer and that it negatively influenced the prognosis of colorectal
cancer patients (Peng et al, 2004), although it is questionable to
involve PRL-3 in prognosis in non-consecutive series.
To date, there are no studies dealing with PRL-3 expression
using the approach of human xenografts in nude mice. Xenografts
are characterised by no contamination of human non-tumoral
cells. Then, using oligonucleotides to amplify the specifically
human sequence of the target gene (PRL-3) and housekeeping
gene, we can ensure not only an enrichment of sample to almost
100% but also that specific expression is not masked for murine
RNA. Such an approach leads us to determine an overexpression of
PRL-3 in LMs seven-fold higher than in primary colorectal
tumours, confirming previously reported descriptive results using
other enrichment techniques (Saha et al, 2001). Giving strength to
the xenograft approach, we evaluated the possible influence of
tumour microenvironment on the expression rates of tumoral
cells. Then, we compared, using human-specific oligonucleotides,
E-cadherin expression between CRC xenografts and paired human
primary tumours showing no differences, confirming the useful-
ness of xenografts to RNA expression purposes and, in particular,
PRL-3 expression. Furthermore, we avoid the contribution of
murine vasculature, although scarce, to PRL-3 levels reported by
other authors (Bardelli et al, 2003).
The assessment of PRL-3 in microdissected matched samples
confirmed that stromal cells (including carcinoma-associated
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Figure 4 (A) Photomicrography ( 200) showing staining with anti-
PRL-3 antibody (1 : 500), both in the tumoral compartment and normal
transition mucosa. (B) Photomicrography ( 400) showing staining with
anti-PRL-3 antibody (1 : 500) in a normal colonic mucosa. (C) Western blot
analysis showing specificity of rabbit antihuman PRL-3 polyclonal antibody
against PRL-3 in its denatured conformation (SDS–PAGE).
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Figure 5 (A) OS (overall survival) and (B) DFS (disease-free survival)
Kaplan–Meier survival plots according to PRL-3 expression status. Eighty
primary metastatic colorectal tumours (46 stage IIIB and 34 stage IIIC) and
their correspondent normal colonic mucosa were obtained from the
Department of Pathology of the Hospital Universitari de Bellvitge. Among
the 80 CRCs, we classify 43 CRC (29 stage IIIB and 14 stage IIIC) that did
not develop distant metastases for at least 60 months and 37 CRCs (17
stage IIIB and 20 stage IIIC) that developed liver or/and lung metastases. All
patients underwent surgical resection – 70 radical surgery and 10 palliative
surgery. All patients received adjuvant chemotherapy treatment. The
median follow-up was 107.30 months (range: 43–132). End points were
local recurrence for DFS and cancer-related death or last follow-up for OS.
At the end of the follow-up period 45out of 80 patients (56.25%) were
alive without disease, six (7.5%) were alive with disease and 29 died of
cancer. PRL-3 expression values were normalised for b2-microglobulin.
Absolute expression of each tumour sample was adjusted for expression of
its paired normal colonic mucosa. P-values correspond to the univariate
model of Cox regression test and were considered significant if Pp0.05.
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fibroblast, inflammatory cells and endothelial cells essentially)
scantly contributed to the total PRL-3 expression and suggested
that the analysis of primary tumours and metastases samples
without tumour cell enrichment could provide meaningful data
about the role of PRL-3. This is especially relevant in the
metastases analyses where stromal reaction is very abundant in
the majority of cases.
Evaluation of PRL-3 in matched triplets normal mucosa,
primary tumour and LMs displayed greater differences in
expression in the step normal mucosa to primary tumour in
comparison with the step primary tumour towards LM. Thus, most
of the overexpression detected in metastases is already present in
the corresponding primary tumours. Altogether, our findings
further suggest that the phosphatase is required for the
processes of migration and invasion both at the primary site and
the secondary site where it is still selected. Finally, it must
be emphasised that no differences were observed regarding
synchronous and metachronous lesions, as suggested by other
authors, although the limited sample size precludes drawing
conclusions.
For the first time, we assessed the expression of PRL-3 isoform 2.
PRL-3 exists in two isoforms – one of 173 amino-acid residues and the
other of 148 amino acids. Isoform 2 is also upregulated in colorectal
primary tumours approximately three-fold higher than in normal
mucosa, but its function, as for isoform 1, remains to be elucidated.
Finally, we explored the hypothesis that PRL-3 could be used as
a marker to select patients with locally advanced CRC (stages IIIB
and IIIC) and predict those with higher risk to relapse in distant
sites. In stage III colorectal carcinoma, approximately 70% of
patients will develop distant metastases, mainly confined to the
liver, during the course of 2 or 3 years after the resection of their
primary tumour (Khatri et al, 2005). Our results point to a putative
clinical value of the semiquantitative PRL-3mRNA level assess-
ment as a prognostic marker in stage III tumours receiving
adjuvant therapy. This technique is a good alternative to ISH and
IHC and provides a more reliable quantitative assessment.
Although Peng et al (2004) have shown that IHC can be a good
alternative (, we have not been able to obtain reproducible
immunostaining results using commercially available antibodies to
date, as these antibodies also stained normal colonic mucosa as
also reported by Peng et al (2004) using 3B6 monoclonal antibody.
Although commercial antibodies are specific for PRL-3 in a
denaturised linear conformation, as we observed by western blot,
perhaps they cannot recognise the antigen in its native conforma-
tion, as immunostaining after blocking with the entire PRL-3
protein reproduces the same pattern.
In summary, the quantitative assessment of PRL-3 mRNA levels
is an adequate tool, and better than IHC, to study routinely
collected tumour samples, as overexpression is apparently
restricted to the tumour cell compartment limiting the impact of
the intensity of tumour stromal reaction on the final quantitative
assessment. Moreover, PRL-3 overexpression is a common event in
stage III colorectal primary tumours that is further selected during
liver dissemination. PRL-3 expression correlates with tumour
aggressiveness and is a promising predictor of distant metastases.
Therefore, the assessment of PRL-3 expression will be of great
interest to identify patients with higher risk of relapse who could
benefit from a more exhaustive surveillance to anticipate the
appearance of disseminated disease, or on the other hand, patients
that have an unexpectedly good outcome despite the presence of
locoregional metastases.
For the purpose of prognosis, it is mandatory to validate the
cutoff value of PRL-3 expression in larger and consecutive series in
the adjuvant setting.
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